ReviewJournal of current glaucoma practice

Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence.

Mary V Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.